EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

αO-Conotoxin GeXIVA[1,2] Suppresses In Vivo Tumor Growth of Triple-Negative Breast Cancer by Inhibiting AKT-mTOR, STAT3 and NF-κB Signaling Mediated Proliferation and Inducing Apoptosis

Xijun Guo, Leping He, Weifeng Xu, Wanrong Wang, Xiaoli Feng, Yuanfeng Fu, Xiaofan Zhang, Ren-Bo Ding, Xingzhu Qi, Jiaolin Bao iD, Sulan Luo iD

Marine Drugs · 2024

DOI: 10.3390/md22060252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, 2024. Verfasst von Xijun Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Collaborative Innovation Center of One H…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Apoptosis, STAT3 Transcription Factor, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hainan Provincial Natural Science Foundation of China, Hainan University Collaborative Innovation Center Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the leading causes of cancer mortality worldwide, and triple-negative breast cancer (TNBC) is the most problematic subtype. There is an urgent need to develop novel drug candidates for TNBC. Marine toxins are a valuable source for drug discovery. We previously identified αO-conotoxin GeXIVA[1,2] from Conus generalis, which is a selective antagonist of α9 nicotinic acetylcholine receptors (nAChRs). Recent studies indicated that α9 nAChR expression is positively correlated with breast cancer development; thus, α9 nAChR could serve as a therapeutic target for breast cancer. In this study, we aimed to investigate the in vivo antitumor effects of GeXIVA[1,2] on TNBC and to elucidate its underlying anticancer mechanism. Our data showed that GeXIVA[1,2] effectively suppressed 4T1 tumor growth in vivo at a very low dose of 0.1 nmol per mouse. Our results uncovered that the antitumor mechanism of GeXIVA[1,2] simultaneously induced apoptosis and blocked proliferation. Further investigations revealed that GeXIVA[1,2]-induced Caspase-3-dependent apoptosis was achieved through regulating Bax/Bcl-2 balance, and GeXIVA[1,2]-inhibited proliferation was mediated by the downregulation of the AKT-mTOR, STAT3 and NF-κB signaling pathways. Our study provides valuable arguments to demonstrate the potential of GeXIVA[1,2] as a novel marine-derived anticancer drug candidate for the treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsApoptosisSTAT3 Transcription FactorTOR Serine-Threonine KinasesNF-kappa BSignal TransductionProto-Oncogene Proteins c-aktCell ProliferationConotoxinsAnimalsFemaleMiceCell Line, TumorMice, Inbred BALB CHumansAntineoplastic Agents

Stichwörter der Autor:innen

GeXIVA[1,2]apoptosisbreast cancerproliferationαO-conotoxin

Substanzen

STAT3 Transcription FactorTOR Serine-Threonine KinasesNF-kappa BProto-Oncogene Proteins c-aktConotoxinsAntineoplastic Agents

Autor:innen und Institutionen

  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Collaborative Innovation Center of One Health, Hainan University, Haikou 570228, China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.
  • Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.

ORCID-Profile: Jiaolin Bao, Sulan Luo

Förderung

  • National Natural Science Foundation of China
  • Hainan Provincial Natural Science Foundation of China
  • Hainan University Collaborative Innovation Center Research Fund
  • Hainan University High-level Talent Start-up Fund
  • Open Research Project Program of the State Key Laboratory of Quality Research in Chinese Medicine (University of Macau)
  • Young Elite Scientists Sponsorship Program by Hainan Association for Science and Technology
  • Hainan “Nanhai New Star” Project

Zitieren

APA

Guo, X., He, L., Xu, W., Wang, W., Feng, X., Fu, Y., Zhang, X., Ding, R. B., Qi, X., Bao, J., & Luo, S. (2024). αO-Conotoxin GeXIVA[1,2] Suppresses In Vivo Tumor Growth of Triple-Negative Breast Cancer by Inhibiting AKT-mTOR, STAT3 and NF-κB Signaling Mediated Proliferation and Inducing Apoptosis. Marine Drugs. https://doi.org/10.3390/md22060252

Vancouver

Guo X, He L, Xu W, Wang W, Feng X, Fu Y, et al. αO-Conotoxin GeXIVA[1,2] Suppresses In Vivo Tumor Growth of Triple-Negative Breast Cancer by Inhibiting AKT-mTOR, STAT3 and NF-κB Signaling Mediated Proliferation and Inducing Apoptosis. Marine Drugs. 2024. doi:10.3390/md22060252

BibTeX
@article{Guo2024,
  author = {Guo, Xijun and He, Leping and Xu, Weifeng and Wang, Wanrong and Feng, Xiaoli and Fu, Yuanfeng and Zhang, Xiaofan and Ding, Ren-Bo and Qi, Xingzhu and Bao, Jiaolin and Luo, Sulan},
  title = {αO-Conotoxin GeXIVA[1,2] Suppresses In Vivo Tumor Growth of Triple-Negative Breast Cancer by Inhibiting AKT-mTOR, STAT3 and NF-κB Signaling Mediated Proliferation and Inducing Apoptosis},
  journal = {Marine Drugs},
  year = {2024},
  doi = {10.3390/md22060252}
}
Kostenlos starten →